LANNETT COMP (NY: LCI)
32.82 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(LCI) Community Analysis from
April 18, 2014
(Stock Blog Hub, 3/5/13)
UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies. The Candidate Tozadenant is an...(read more)
(Stock Blog Hub, 10/9/12)
Lannett Company, Inc. (LCI) recently announced that the US Food and Drug Administration (FDA) granted approval to the company’s abbreviated new drug application (ANDA) for its generic...(read more)
(Benzinga, 9/13/10)
Lannett Co. Inc. (NYSE: LCI) reports Q4 EPS of $0.11, versus the consensus of $0.08. Lannett Co. Inc. reports revenues of $33.8 million, versus the consensus of $32.03 million. "Strong sales of our pain management drugs in the...(read more)
Lannett Co (LCI) Company Overview

There is no analysis for LCI yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here